Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein

Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome (MERS)–associated coronavirus. Here, we report that cross-reactive monkeypox virus neutralizing antibodies were...

Descripción completa

Detalles Bibliográficos
Autores principales: Raadsen, Matthijs P, Dahlke, Christine, Fathi, Anahita, Lamers, Mart M, van den Doel, Petra, Zaeck, Luca M, van Royen, Martin E, de Bruin, Erwin, Sikkema, Reina, Koopmans, Marion, van Gorp, Eric C M, Sutter, Gerd, de Vries, Rory D, Addo, Marylyn M, Haagmans, Bart L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469103/
https://www.ncbi.nlm.nih.gov/pubmed/36857443
http://dx.doi.org/10.1093/infdis/jiad052
Descripción
Sumario:Modified vaccinia virus Ankara (MVA) is used as a vaccine against monkeypox virus and as a viral vaccine vector. MVA-MERS-S is a vaccine candidate against Middle East respiratory syndrome (MERS)–associated coronavirus. Here, we report that cross-reactive monkeypox virus neutralizing antibodies were detectable in only a single study participant after the first dose of MVA-MERS-S vaccine, in 3 of 10 after the second dose, and in 10 of 10 after the third dose.

Ejemplares similares